000293311 001__ 293311
000293311 005__ 20250305161041.0
000293311 0247_ $$2doi$$a10.3174/ajnr.A8496
000293311 0247_ $$2pmid$$apmid:39271290
000293311 0247_ $$2ISSN$$a0195-6108
000293311 0247_ $$2ISSN$$a1936-959X
000293311 037__ $$aDKFZ-2024-01869
000293311 041__ $$aEnglish
000293311 082__ $$a610
000293311 1001_ $$aTietze, A.$$b0
000293311 245__ $$aCNS Embryonal Tumor with PLAGL Amplification, a New Tumor Type in Children and Adolescents: Insights from a Comprehensive MRI Analysis.
000293311 260__ $$aOak Brook, Ill.$$bSoc.$$c2025
000293311 3367_ $$2DRIVER$$aarticle
000293311 3367_ $$2DataCite$$aOutput Types/Journal article
000293311 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1741187400_6627
000293311 3367_ $$2BibTeX$$aARTICLE
000293311 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000293311 3367_ $$00$$2EndNote$$aJournal Article
000293311 500__ $$a2025 Mar 4;46(3):536-543
000293311 520__ $$aCNS embryonal tumor with PLAGL1/PLAGL2 amplification (ET, PLAGL) is a newly identified, highly malignant pediatric tumor. Systematic MRI descriptions of ET, PLAGL are currently lacking.MRI data from 19 treatment-naïve patients with confirmed ET, PLAGL were analyzed. Evaluation focused on anatomical involvement, tumor localization, MRI signal characteristics, DWI behavior, and the presence of necrosis and hemorrhage. Descriptive statistics (median, interquartile range, percentage) were assessed.Ten patients had PLAGL1 and nine PLAGL2 amplifications. The solid components of the tumors were often multinodular with heterogeneous enhancement (mild to intermediate in 47% and intermediate to strong in 47% of cases). Non-solid components included cysts in 47% and necrosis in 84% of the cases. The tumors showed heterogeneous T2WI hyper-and isointensity (74%), relatively little diffusion restriction (ADC values < contralateral normal-appearing WM in 36% of cases with available DWI), and tendencies towards hemorrhage/calcification (42%). No reliable distinction was found between PLAGL1-and PLAGL2-amplified tumors or compared to other embryonal CNS tumors.The study contributes to understanding the imaging characteristics of ET, PLAGL. It underscores the need for collaboration in studying rare pediatric tumors and advocates for the use of harmonized imaging protocols for better characterization.ATRT= atypical teratoid/rhabdoid tumor; ETMR= embryonal tumor with multilayered rosettes; ET, PLAGL= CNS embryonal tumor with PLAGL amplification; EVD= external ventricular drain; IQR: interquartile range; PLAGL1= pleomorphic adenoma gene-like 1; PLAGL2= pleomorphic adenoma gene-like 2; WHO= World Health Organization.
000293311 536__ $$0G:(DE-HGF)POF4-312$$a312 - Funktionelle und strukturelle Genomforschung (POF4-312)$$cPOF4-312$$fPOF IV$$x0
000293311 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000293311 7001_ $$aBison, B.$$b1
000293311 7001_ $$aOncology, European Society for Paediatric$$b2$$eCollaboration Author
000293311 7001_ $$aEngelhardt, J.$$b3
000293311 7001_ $$aFenouil, T.$$b4
000293311 7001_ $$aFigarella-Branger, D.$$b5
000293311 7001_ $$aGoebell, E.$$b6
000293311 7001_ $$aHakumäki, J.$$b7
000293311 7001_ $$aKoscielniak, E.$$b8
000293311 7001_ $$aLudlow, L. E.$$b9
000293311 7001_ $$aMeyronet, D.$$b10
000293311 7001_ $$aNyman, P.$$b11
000293311 7001_ $$aØra, I.$$b12
000293311 7001_ $$aPesola, J.$$b13
000293311 7001_ $$aRauramaa, T.$$b14
000293311 7001_ $$aReddingius, R. E.$$b15
000293311 7001_ $$aSamuel, D.$$b16
000293311 7001_ $$aSexton-Oates, A.$$b17
000293311 7001_ $$aVasiljevic, A.$$b18
000293311 7001_ $$aWefers, A. K.$$b19
000293311 7001_ $$aZamecnik, J.$$b20
000293311 7001_ $$aJones, Dtw$$b21
000293311 7001_ $$0P:(DE-He78)9f1196ab1abb80483e1f69e8c0c4172d$$aKeck, M. K.$$b22$$udkfz
000293311 7001_ $$avon Hoff, K.$$b23
000293311 7001_ $$aAvula, S.$$b24$$eContributor
000293311 7001_ $$aFaure-Conter, C.$$b25$$eContributor
000293311 7001_ $$aBison, B.$$b26$$eContributor
000293311 7001_ $$aGojo, J.$$b27$$eContributor
000293311 7001_ $$aHaberler, C.$$b28$$eContributor
000293311 7001_ $$aHayden, J. T.$$b29$$eContributor
000293311 7001_ $$aJohann, P. D.$$b30$$eContributor
000293311 7001_ $$0P:(DE-He78)551bb92841f634070997aa168d818492$$aJones, D.$$b31$$eContributor$$udkfz
000293311 7001_ $$aKorhonen, L. S.$$b32$$eContributor
000293311 7001_ $$aKramm, C.$$b33$$eContributor
000293311 7001_ $$aKranendonk, Meg$$b34$$eContributor
000293311 7001_ $$aLequin, M.$$b35$$eContributor
000293311 7001_ $$aPerwein, T.$$b36$$eContributor
000293311 7001_ $$aSchouten-van Meeteren, Ayn$$b37$$eContributor
000293311 7001_ $$aTietze, A.$$b38$$eContributor
000293311 7001_ $$avon Kalle, T.$$b39$$eContributor
000293311 7001_ $$avon Zezschwitz, B.$$b40$$eContributor
000293311 7001_ $$aWesseling, P.$$b41$$eContributor
000293311 7001_ $$aZapotocky, M.$$b42$$eContributor
000293311 7001_ $$avon Hoff, K.$$b43$$eContributor
000293311 773__ $$0PERI:(DE-600)2025541-X$$a10.3174/ajnr.A8496$$gp. ajnr.A8496 -$$n3$$p536-543$$tAmerican journal of neuroradiology$$v46$$x0195-6108$$y2025
000293311 909CO $$ooai:inrepo02.dkfz.de:293311$$pVDB
000293311 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)9f1196ab1abb80483e1f69e8c0c4172d$$aDeutsches Krebsforschungszentrum$$b22$$kDKFZ
000293311 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)551bb92841f634070997aa168d818492$$aDeutsches Krebsforschungszentrum$$b31$$kDKFZ
000293311 9131_ $$0G:(DE-HGF)POF4-312$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunktionelle und strukturelle Genomforschung$$x0
000293311 9141_ $$y2024
000293311 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-24
000293311 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-10-24
000293311 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-24
000293311 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-10-24
000293311 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-10-24
000293311 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-24
000293311 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2023-10-24
000293311 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2023-10-24
000293311 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-10-24
000293311 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-10-24
000293311 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bAM J NEURORADIOL : 2022$$d2023-10-24
000293311 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-24
000293311 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2023-10-24
000293311 9201_ $$0I:(DE-He78)B360-20160331$$kB360$$lPädiatrische Gliomforschung$$x0
000293311 980__ $$ajournal
000293311 980__ $$aVDB
000293311 980__ $$aI:(DE-He78)B360-20160331
000293311 980__ $$aUNRESTRICTED